Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance
出版年份 2020 全文链接
标题
Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance
作者
关键词
-
出版物
BRITISH JOURNAL OF CANCER
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-12-03
DOI
10.1038/s41416-020-01157-0
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma
- (2020) Melanie A. Krook et al. MOLECULAR CANCER THERAPEUTICS
- Pan-cancer analysis of FGFR1-3 genomic alterations to reveal a complex molecular landscape.
- (2020) Melanie A. Krook et al. JOURNAL OF CLINICAL ONCOLOGY
- Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
- (2020) Ghassan K Abou-Alfa et al. LANCET ONCOLOGY
- TAS-120 Cancer Target Binding: Defining Reactivity and Revealing the First Fibroblast Growth Factor Receptor 1 (FGFR1) Irreversible Structure
- (2019) Maria Kalyukina et al. ChemMedChem
- Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines
- (2019) Claudia Fumarola et al. Frontiers in Oncology
- Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors
- (2019) Rastilav Bahleda et al. CLINICAL CANCER RESEARCH
- High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no driver alteration detected by DNA sequencing and low tumor mutation burden
- (2019) Ryma Benayed et al. CLINICAL CANCER RESEARCH
- Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase 3 study design
- (2019) Daniel VT Catenacci et al. Future Oncology
- A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma
- (2019) Emilie M. J. van Brummelen et al. INVESTIGATIONAL NEW DRUGS
- FIERCE-22: Clinical activity of vofatamab (V) a FGFR3 selective inhibitor in combination with pembrolizumab (P) in WT metastatic urothelial carcinoma, preliminary analysis.
- (2019) Arlene O. Siefker-Radtke et al. JOURNAL OF CLINICAL ONCOLOGY
- Updated results of a phase IIa study to evaluate the clinical efficacy and safety of erdafitinib in Asian advanced cholangiocarcinoma (CCA) patients with FGFR alterations.
- (2019) Joon Oh Park et al. JOURNAL OF CLINICAL ONCOLOGY
- Baseline cfDNA characteristics and evolution of cfDNA profile during treatment with selective FGFR inhibitor TAS-120.
- (2019) Tyler J. Moss et al. JOURNAL OF CLINICAL ONCOLOGY
- Non-invasive detection of acquired resistance to FGFR inhibition in patients with cholangiocarcinoma harboring FGFR2 alterations.
- (2019) Anna M. Varghese et al. JOURNAL OF CLINICAL ONCOLOGY
- TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma
- (2019) Lipika Goyal et al. Cancer Discovery
- A functional CRISPR/Cas9 screen identifies kinases that modulate FGFR inhibitor response in gastric cancer
- (2019) Jiamin Chen et al. Oncogenesis
- Phase II study of Dovitinib in recurrent glioblastoma
- (2019) Mayur Sharma et al. JOURNAL OF NEURO-ONCOLOGY
- Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
- (2019) Yohann Loriot et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular Profiling Reclassifies Adult Astroblastoma into Known and Clinically Distinct Tumor Entities with Frequent Mitogen‐Activated Protein Kinase Pathway Alterations
- (2019) William Boisseau et al. ONCOLOGIST
- Fibroblast Growth Factor Receptors (FGFRs): Structures and Small Molecule Inhibitors
- (2019) Shuyan Dai et al. Cells
- Circular RNA circ-ZKSCAN1 inhibits bladder cancer progression through miR-1178-3p/p21 axis and acts as a prognostic factor of recurrence
- (2019) Junming Bi et al. Molecular Cancer
- First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody–Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer
- (2019) Sung-Bae Kim et al. Targeted Oncology
- First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant Fibroblast Growth Factor 19 Signaling as a Driver Event in Hepatocellular Carcinoma
- (2019) Richard D Kim et al. Cancer Discovery
- Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study
- (2019) Martin Schuler et al. LANCET ONCOLOGY
- An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer
- (2019) Daniel Morgensztern et al. LUNG CANCER
- Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
- (2019) Robert C Doebele et al. LANCET ONCOLOGY
- Basket Studies: Redefining Clinical Trials in the Era of Genome-Driven Oncology
- (2018) Jessica J. Tao et al. Annual Review of Medicine
- ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties
- (2018) Merrida A Childress et al. MOLECULAR CANCER RESEARCH
- FGFR2 amplification is predictive of sensitivity to regorafenib in gastric and colorectal cancers in vitro
- (2018) Yongjun Cha et al. Molecular Oncology
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
- (2018) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1–3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations
- (2018) Sumanta K. Pal et al. Cancer Discovery
- Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer
- (2018) Navid Sobhani et al. Cells
- The roles of fibroblast growth factor receptor 4 in cancers
- (2018) Shuya Tang et al. CANCER SCIENCE
- Preselection of lung cancer cases using FGFR1 mRNA and gene copy number for treatment with ponatinib.
- (2018) Terry L. Ng et al. Clinical Lung Cancer
- FIERCE-21: Phase 1b/2 study of docetaxel + b-701, a selective inhibitor of FGFR3, in relapsed or refractory (R/R) metastatic urothelial carcinoma (mUCC).
- (2018) Joaquim Bellmunt et al. JOURNAL OF CLINICAL ONCOLOGY
- Detection of known and novel FGFR fusions in non-small cell lung cancer by comprehensive genomic profiling
- (2018) Angel Qin et al. Journal of Thoracic Oncology
- LBA28Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions
- (2018) M Javle et al. ANNALS OF ONCOLOGY
- 900PInterim results of fight-201, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with metastatic or surgically unresectable urothelial carcinoma (UC) harboring fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations (GA)
- (2018) A Necchi et al. ANNALS OF ONCOLOGY
- Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
- (2018) Vincenzo Mazzaferro et al. BRITISH JOURNAL OF CANCER
- ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity
- (2018) Tim H. Holmström et al. MOLECULAR CANCER THERAPEUTICS
- Fibroblast growth factor receptors as treatment targets in clinical oncology
- (2018) Masaru Katoh Nature Reviews Clinical Oncology
- Enhanced detection of circulating tumor DNA by fragment size analysis
- (2018) Florent Mouliere et al. Science Translational Medicine
- Metastatic Calcinosis Cutis Associated With a Selective FGFR Inhibitor
- (2018) David R. Carr et al. JAMA Dermatology
- Mutation in the FGFR1 tyrosine kinase domain or inactivation of PTEN is associated with acquired resistance to FGFR inhibitors in FGFR1-driven leukemia/lymphomas
- (2017) John K. Cowell et al. INTERNATIONAL JOURNAL OF CANCER
- Validation of a Targeted RNA Sequencing Assay for Kinase Fusion Detection in Solid Tumors
- (2017) Julie W. Reeser et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor
- (2017) Timothy P.S. Perera et al. MOLECULAR CANCER THERAPEUTICS
- Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
- (2017) Solange Peters et al. NEW ENGLAND JOURNAL OF MEDICINE
- AACR Project GENIE: Powering Precision Medicine through an International Consortium
- (2017) Cancer Discovery
- Severe Onycholysis and Eyelash Trichomegaly Following Use of New Selective Pan-FGFR Inhibitors
- (2017) Sarah Bétrian et al. JAMA Dermatology
- Missing the mark inFGFR1-amplified squamous cell cancer of the lung
- (2016) Paul K. Paik et al. CANCER
- Preclinical Efficacy of the Auristatin-Based Antibody–Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors
- (2016) Anette Sommer et al. CANCER RESEARCH
- FGFRgene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib
- (2016) Masaaki Hibi et al. CANCER SCIENCE
- A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157
- (2016) Noah M. Hahn et al. CLINICAL CANCER RESEARCH
- Targeting FGFR2 with alofanib (RPT835) shows potent activity in tumour models
- (2016) Ilya Tsimafeyeu et al. EUROPEAN JOURNAL OF CANCER
- FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)
- (2016) MASARU KATOH INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors
- (2016) Yongkun Sun et al. Journal of Hematology & Oncology
- Activity and safety of brigatinib in ALK -rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial
- (2016) Scott N Gettinger et al. LANCET ONCOLOGY
- Polyclonal SecondaryFGFR2Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma
- (2016) Lipika Goyal et al. Cancer Discovery
- Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use
- (2016) Harshnira Patani et al. Oncotarget
- Crystal Structure of the FGFR4/LY2874455 Complex Reveals Insights into the Pan-FGFR Selectivity of LY2874455
- (2016) Daichao Wu et al. PLoS One
- A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors
- (2015) A. W. Tolcher et al. ANNALS OF ONCOLOGY
- Rationale for targeting fibroblast growth factor receptor signaling in breast cancer
- (2015) Fabrice André et al. BREAST CANCER RESEARCH AND TREATMENT
- FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers
- (2015) F. Goke et al. CLINICAL CANCER RESEARCH
- The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing
- (2015) T. Helsten et al. CLINICAL CANCER RESEARCH
- Functions of Fibroblast Growth Factor Receptors in cancer defined by novel translocations and mutations
- (2015) Leandro H. Gallo et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Ponatinib: Accelerated Disapproval
- (2015) J. F. Gainor et al. ONCOLOGIST
- The Fibroblast Growth Factor signaling pathway
- (2015) David M. Ornitz et al. Wiley Interdisciplinary Reviews-Developmental Biology
- Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in FGFR2 amplified gastric cancer
- (2015) Jinjia Chang et al. Oncotarget
- The N550K/H Mutations in FGFR2 Confer Differential Resistance to PD173074, Dovitinib, and Ponatinib ATP-Competitive Inhibitors
- (2015) Sara A Byron et al. NEOPLASIA
- Physiological Functions and Underlying Mechanisms of Fibroblast Growth Factor (FGF) Family Members: Recent Findings and Implications for Their Pharmacological Application
- (2014) Toru Imamura BIOLOGICAL & PHARMACEUTICAL BULLETIN
- Pazopanib, a Novel Multitargeted Kinase Inhibitor, Shows Potent In Vitro Antitumor Activity in Gastric Cancer Cell Lines with FGFR2 Amplification
- (2014) S. T. Kim et al. MOLECULAR CANCER THERAPEUTICS
- Anchored multiplex PCR for targeted next-generation sequencing
- (2014) Zongli Zheng et al. NATURE MEDICINE
- COSMIC: exploring the world's knowledge of somatic mutations in human cancer
- (2014) Simon A. Forbes et al. NUCLEIC ACIDS RESEARCH
- Functional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancers
- (2013) Kai Hung Tiong et al. APOPTOSIS
- Fibroblast growth factor receptor 1 amplification is a common event in squamous cell carcinoma of the head and neck
- (2013) Friederike Göke et al. MODERN PATHOLOGY
- Blockade of Nonhormonal Fibroblast Growth Factors by FP-1039 Inhibits Growth of Multiple Types of Cancer
- (2013) T. C. Harding et al. Science Translational Medicine
- Pan-FGFR Inhibition Leads to Blockade of FGF23 Signaling, Soft Tissue Mineralization, and Cardiovascular Dysfunction
- (2013) Gina M. Yanochko et al. TOXICOLOGICAL SCIENCES
- Identification of Targetable FGFR Gene Fusions in Diverse Cancers
- (2013) Yi-Mi Wu et al. Cancer Discovery
- 621 A Phase I Dose-escalation Study of MFGR1877S, a Human Monoclonal Anti-fibroblast Growth Factor Receptor 3 (FGFR3) Antibody, in Patients (pts) with Advanced Solid Tumors
- (2012) P. ODonnell et al. EUROPEAN JOURNAL OF CANCER
- Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma
- (2012) D. Singh et al. SCIENCE
- GP369, an FGFR2-IIIb-Specific Antibody, Exhibits Potent Antitumor Activity against Human Cancers Driven by Activated FGFR2 Signaling
- (2010) A. Bai et al. CANCER RESEARCH
- Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice
- (2009) Jing Qing et al. JOURNAL OF CLINICAL INVESTIGATION
- Transcriptome sequencing to detect gene fusions in cancer
- (2009) Christopher A. Maher et al. NATURE
- The FGFR4 Y367C mutant is a dominant oncogene in MDA-MB453 breast cancer cells
- (2009) A Roidl et al. ONCOGENE
- The Precise Sequence of FGF Receptor Autophosphorylation Is Kinetically Driven and Is Disrupted by Oncogenic Mutations
- (2009) E. D. Lew et al. Science Signaling
- Drug-sensitive FGFR2 mutations in endometrial carcinoma
- (2008) A. Dutt et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started